BMO Capital analyst Kostas Biliouris has maintained their bullish stance on ALNY stock, giving a Buy rating today.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight Alnylam Pharma’s leadership in the RNA interference (RNAi) space. The company has demonstrated significant scientific advancements, particularly with its transition from Onpattro’s Q3W IV regimen to Nucresiran’s Q26W subcutaneous regimen, which showcases superior efficacy. This progression underscores Alnylam’s capacity to expand its scientific prowess into various tissues and indications, promising a robust pipeline that could potentially elevate the company to a market cap of approximately $100 billion.
Moreover, Alnylam’s pipeline includes promising programs targeting Huntington’s disease, obesity, and age-related macular degeneration (AMD), which could yield best-in-class or first-in-class therapies. The company’s confidence in Nucresiran’s efficacy is further evidenced by the ATTR-CM Phase III design, which suggests a faster and more significant benefit compared to competitors. Additionally, Alnylam’s growing metabolic pipeline and potential commercial opportunities in dry AMD, supported by promising preclinical data, further reinforce the positive outlook for the company’s future growth and market presence.
In another report released today, Needham also maintained a Buy rating on the stock with a $320.00 price target.